“Mean Percent PASI Improvement With Bimekizumab in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results from Four Phase 3 3b Trials”. 2021. SKIN The Journal of Cutaneous Medicine 5 (6): s55. https://doi.org/10.25251/skin.5.supp.55.